Current concepts in secondary prevention after acute myocardial infarction

被引:5
作者
Mehta, RH
Bossone, E
Eagle, KA
机构
[1] Univ Michigan, Dept Internal Med, Div Cardiol, Ann Arbor, MI 48105 USA
[2] Vet Affairs Med Ctr, Ann Arbor, MI 48105 USA
关键词
myocardial infarction; coronary artery disease; secondary prevention; pharmacologic therapy; smoking; cardiac rehabilitation;
D O I
10.1007/BF03044123
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acute myocardial infarction (MI) is the leading cause of death around the globe. Advances in the field of cardiology have identified several effective treatments that have lead to decrease in mortality from this cause over the past 3 decades. The purpose of this article is to review the existing literature in regards to secondary prevention after acute MI. A search of MEDLINE through August of 1999 was carried out to identify any available publications on secondary prevention after MI. Evidence on the use of both pharmacological and nonpharmacological interventions that was shown to be effective in improving morbidity and mortality was sought. Recommendations for the treatment of patients with acute MI are made based on existing evidence. Betablockers, aspirin and lipid-lowering agents for patients with low density lipoprotein-cholesterol > 130 mg% should be used for all patients following a MI. Angiotensin converting enzyme inhibitors are indicated for patients with congestive heart failure and/or reduced left ventricular ejection fraction and are likely protective in most patients. Calcium channel blockers (Verapamil and Diltiazem) are indicated as second-line therapy for patients who have contraindications or are intolerant to betablockers. The routine prophylactic use of antiarrhythmic drugs to suppress ventricular ectopic beats should be avoided. Recommendations regarding diet, smoking cessation and achievement of ideal body weight should be an integral part of patient management. Referral for outpatient rehabilitation should also be strongly encouraged. Finally, adequate control of blood pressure and diabetes cannot be overemphasized. Adherence to these goals in patients with acute MI will lead to better long-term outcomes and reduction in cardiac death, recurrent MI, stroke, and need for coronary revascularization.
引用
收藏
页码:47 / 60
页数:16
相关论文
共 50 条
[41]   Thrombus aspiration in acute myocardial infarction: concepts, clinical trials, and current guidelines [J].
Vandermolen, Sebastian ;
Marciniak, Maciej ;
Byrne, Jonathan ;
De Silva, Kalpa .
CORONARY ARTERY DISEASE, 2016, 27 (03) :233-243
[42]   Role of psychosocial factors in long-term adherence to secondary prevention measures after myocardial infarction: a longitudinal analysis [J].
Nachshol, Michal ;
Lurie, Ido ;
Benyamini, Yael ;
Goldbourt, Uri ;
Gerber, Yariv .
ANNALS OF EPIDEMIOLOGY, 2020, 52 :35-41
[43]   Long-Term Effects of an Intensive Prevention Program After Acute Myocardial Infarction [J].
Osteresch, Rico ;
Fach, Andreas ;
Frielitz, Fabian-Simon ;
Meyer, Sven ;
Schmucker, Johannes ;
Ruehle, Stephan ;
Retzlaff, Tina ;
Hadwiger, Moritz ;
Haerle, Tobias ;
Elsaesser, Albrecht ;
Katalinic, Alexander ;
Eitel, Ingo ;
Hambrecht, Rainer ;
Wienbergen, Harm .
AMERICAN JOURNAL OF CARDIOLOGY, 2021, 154 :7-13
[44]   WHAT DO WE REALLY KNOW ABOUT SECONDARY PREVENTION AFTER MYOCARDIAL-INFARCTION [J].
WIELGOSZ, AT .
CANADIAN JOURNAL OF CARDIOLOGY, 1995, 11 :A31-A32
[45]   The boundaries between primary and secondary prevention with defibrillators after acute myocardial infarction: Gray areas of the terminology and definition [J].
Kara, Meryem ;
Korkmaz, Ahmet ;
Ozeke, Ozcan ;
Cay, Serkan ;
Ozcan, Firat ;
Topaloglu, Serkan ;
Aras, Dursun .
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2020, 31 (07) :1888-1889
[46]   Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence [J].
Bauer, Timm ;
Gitt, Anselm K. ;
Juenger, Claus ;
Zahn, Ralf ;
Koeth, Oliver ;
Towae, Frank ;
Schwarz, Arne K. ;
Bestehorn, Kurt ;
Senges, Jochen ;
Zeymer, Uwe .
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2010, 17 (05) :576-581
[47]   Association of Diabetes Mellitus Status and Glycemic Control With Secondary Prevention Medication Adherence After Acute Myocardial Infarction [J].
Adamek, Kylie E. ;
Ramadurai, Deepa ;
Gunzburger, Elise ;
Plomondon, Mary E. ;
Ho, P. Michael ;
Raghavan, Sridharan .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (03)
[48]   Persistence of Secondary Prevention Medications after Acute Myocardial Infarction: Insights from the TRANSLATE-ACS Study [J].
Mathews, Robin ;
Wang, Tracy Y. ;
Honeycutt, Emily ;
Henry, Timothy D. ;
Chang, Michael ;
Fonarow, Gregg C. ;
Peterson, Eric D. .
CIRCULATION, 2012, 126 (21)
[49]   Association Between Secondary Prevention Medication Use and Outcomes in Frail Older Adults After Acute Myocardial Infarction [J].
Zullo, Andrew R. ;
Mogul, Amanda ;
Corsi, Katherine ;
Shah, Nishant R. ;
Lee, Sei J. ;
Rudolph, James L. ;
Wu, Wen-Chih ;
Dapaah-Afriyie, Ruth ;
Berard-Collins, Christine ;
Steinman, Michael A. .
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2019, 12 (04)
[50]   Effects of adherence to pharmacological secondary prevention after acute myocardial infarction on health care costs - an analysis of real-world data [J].
Kirsch, Florian ;
Becker, Christian ;
Kurz, Christoph ;
Schwettmann, Lars ;
Schramm, Anja .
BMC HEALTH SERVICES RESEARCH, 2020, 20 (01)